Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial

BACKGROUND: The US Food and Drug Administration approved sacubitril/valsartan for patients with chronic heart failure (HF) with reduced ejection fraction in 2015 on the basis of the results of the PARADIGM‐HF (Prospective Comparison of ARNI [Angiotensin Receptor Neprilysin Inhibitor] With ACEI [Angi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Am Heart Assoc
Autori principali: DeVore, Adam D., Mi, Xiaojuan, Thomas, Laine, Sharma, Puza P., Albert, Nancy M., Butler, Javed, Hernandez, Adrian F., Patterson, J. Herbert, Spertus, John A., Williams, Fredonia B., Duffy, Carol I., McCague, Kevin, Fonarow, Gregg C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2018
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220559/
https://ncbi.nlm.nih.gov/pubmed/29895587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.009237
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi